Compare Inovio Pharmaceuticals Inc (INO) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Yum China Holdings Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Yum China Holdings Inc trades at $42.86 (market cap $15.09B). The key difference: Yum China Holdings Inc is far larger — about 169× Inovio Pharmaceuticals Inc's market cap, and Yum China Holdings Inc pays a 2.64% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | YUMC | |
|---|---|---|
Market Cap | $89.27M | $15.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $57.95 |
52-Week Low | $1.05 | $40.18 |
Enterprise Value | $60.28M | $15.98B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
YUMC trades at $43.92, up 0.11% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $11.80B in 2025, and profitability remains solid with a 7.83% net margin. The acquisition of Pizza Hut China ownership is a strategic move expected to enhance margins.
The outlook is positive with strong analyst support (73.68% buy ratings), but risks include China's macroeconomic headwinds and competitive pressures. Valuation appears reasonable with a P/E of 16.81, suggesting potential for upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
